Lipitor In The Prevention Of Stroke, For Patients Who Have Had A Previous Stroke - Full Text View

Sponsored by:	Pfizer
Information provided by:	Pfizer
ClinicalTrials.gov Identifier:	NCT00147602

Purpose

To determine whether Lipitor reduces stroke, compared to placebo in patients who have had a previous stroke or transient ischemic attack.

Condition	Intervention	Phase
Cardiovascular Disease	Drug: atorvastatin	Phase IV

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study
Official Title:	A Double-Blind, Randomized, Placebo- Controlled Study Of Atorvastatin As Prevention Of Cerebrovascular Events In Patients With A Previous Transient Ischemic Attack (TIA) Or Stroke

Resource links provided by NLM:

MedlinePlus related topics: Transient Ischemic Attack

Drug Information available for: Atorvastatin Atorvastatin calcium

U.S. FDA Resources

Further study details as provided by Pfizer:

Primary Outcome Measures:

Time to occurrence of fatal or non-fatal stroke

Secondary Outcome Measures:

Time to occurrence of an acute coronary event, consisting of cardiac death, nonfatal myocardial infarction, resuscitated cardiac arrest or unstable angina.
Time to occurrence of a cerebrovascular event, defined as fatal or nonfatal stroke or TIA.

Estimated Enrollment:	4732
Study Start Date:	November 1998
Estimated Study Completion Date:	November 2005

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Previous stroke or TIA

Exclusion Criteria:

coronary heart disease

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00147602

Show 130 Study Locations

Sponsors and Collaborators

Pfizer

Investigators

Study Director:

Pfizer CT.gov Call Center

Pfizer

More Information

Additional Information:

Links to ClinicalStudyResults.org Posting: This link exits the ClinicalTrials.gov site

Publications:

Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE, Sillesen H, Simunovic L, Szarek M, Welch KM, Zivin JA; Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006 Aug 10;355(6):549-59.

Additional publications automatically indexed to this study by National Clinical Trials Identifier (NCT ID):

Amarenco P, Goldstein LB, Callahan A 3rd, Sillesen H, Hennerici MG, O'Neill BJ, Rudolph AE, Simunovic L, Zivin JA, Welch KM; SPARCL Investigators. Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Atherosclerosis. 2009 Jun;204(2):515-20. Epub 2008 Sep 18.

Study ID Numbers:	0981-342, A2581138
Study First Received:	September 6, 2005
Last Updated:	May 1, 2007
ClinicalTrials.gov Identifier:	NCT00147602 History of Changes
Health Authority:	United States: Food and Drug Administration

Study placed in the following topic categories:

Antimetabolites
Ischemic Attack, Transient
Cerebral Infarction
Antilipemic Agents
Stroke
Vascular Diseases
Central Nervous System Diseases

Ischemia
Anticholesteremic Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Brain Diseases
Cerebrovascular Disorders
Brain Ischemia
Atorvastatin

Additional relevant MeSH terms:

Antimetabolites
Ischemic Attack, Transient
Molecular Mechanisms of Pharmacological Action
Antilipemic Agents
Nervous System Diseases
Vascular Diseases
Central Nervous System Diseases
Enzyme Inhibitors
Anticholesteremic Agents

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Brain Diseases
Cerebrovascular Disorders
Pharmacologic Actions
Therapeutic Uses
Brain Ischemia
Cardiovascular Diseases
Atorvastatin

ClinicalTrials.gov processed this record on September 04, 2009